{
    "id": 22500,
    "fullName": "SMO D384N",
    "impact": "missense",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "SMO D384N lies within the drug-binding pocket of the Smo protein (PMID: 25759019). D384N has been demonstrated to confer resistance to Hedgehog pathway inhibitors (PMID: 25759019), but has not been biochemically characterized and therefore, its effect on Smo protein function is unknown (PubMed, Nov 2019).",
            "references": [
                {
                    "id": 285,
                    "pubMedId": null,
                    "title": null,
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                },
                {
                    "id": 5520,
                    "pubMedId": 25759019,
                    "title": "Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25759019"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 6608,
        "geneSymbol": "SMO",
        "terms": [
            "SMO",
            "CRJS",
            "FZD11",
            "Gx",
            "SMOH"
        ]
    },
    "variant": "D384N",
    "createDate": "05/12/2016",
    "updateDate": "11/04/2019",
    "referenceTranscriptCoordinates": {
        "id": 123173,
        "transcript": "NM_005631",
        "gDna": "chr7:g.129206473G>A",
        "cDna": "c.1150G>A",
        "protein": "p.D384N",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 6328,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Posaconazole inhibited Hedghog signaling in mouse fibroblasts over expressing murine SMO D388N (corresponding to human SMO D384N) in culture (PMID: 26823493).",
            "molecularProfile": {
                "id": 23085,
                "profileName": "SMO D384N"
            },
            "therapy": {
                "id": 4108,
                "therapyName": "Posaconazole",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5515,
                    "pubMedId": 26823493,
                    "title": "Posaconazole, a Second-Generation Triazole Antifungal Drug, Inhibits the Hedgehog Signaling Pathway and Progression of Basal Cell Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26823493"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6332,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination of Posaconazole and Trisenox (Arsenic trioxide) demonstrated enhanced inhibition of Hedghog signaling in mouse fibroblasts over expressing murine SMO D388N (corresponding to human SMO D384N) in culture (PMID: 26823493).",
            "molecularProfile": {
                "id": 23085,
                "profileName": "SMO D384N"
            },
            "therapy": {
                "id": 4117,
                "therapyName": "Arsenic trioxide + Posaconazole",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5515,
                    "pubMedId": 26823493,
                    "title": "Posaconazole, a Second-Generation Triazole Antifungal Drug, Inhibits the Hedgehog Signaling Pathway and Progression of Basal Cell Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26823493"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6315,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed mouse fibroblast cells over expressing murine SMO D388N (corresponding to human SMO D384N) were resistant to Erivedge (vismodegib) induced Hedgehog pathway inhibition in cell culture (PMID: 26823493).",
            "molecularProfile": {
                "id": 23085,
                "profileName": "SMO D384N"
            },
            "therapy": {
                "id": 956,
                "therapyName": "Vismodegib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5515,
                    "pubMedId": 26823493,
                    "title": "Posaconazole, a Second-Generation Triazole Antifungal Drug, Inhibits the Hedgehog Signaling Pathway and Progression of Basal Cell Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26823493"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6313,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed mouse fibroblast cells over expressing murine SMO D388N (corresponding to human SMO D384N) were resistant to Odomzo (sonidegib) induced Hedgehog pathway inhibition in cell culture (PMID: 26823493).",
            "molecularProfile": {
                "id": 23085,
                "profileName": "SMO D384N"
            },
            "therapy": {
                "id": 1428,
                "therapyName": "Sonidegib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5515,
                    "pubMedId": 26823493,
                    "title": "Posaconazole, a Second-Generation Triazole Antifungal Drug, Inhibits the Hedgehog Signaling Pathway and Progression of Basal Cell Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26823493"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6305,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, mouse sarcoma cell lines over expressing SMO D384N demonstrated reduced response to Erivedge (vismodegib) induced Hedgehog pathway inhibition in cell culture (PMID: 25759019).",
            "molecularProfile": {
                "id": 23085,
                "profileName": "SMO D384N"
            },
            "therapy": {
                "id": 956,
                "therapyName": "Vismodegib",
                "synonyms": null
            },
            "indication": {
                "id": 1115,
                "name": "sarcoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 5520,
                    "pubMedId": 25759019,
                    "title": "Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25759019"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        }
    ],
    "molecularProfiles": [
        {
            "id": 23085,
            "profileName": "SMO D384N",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 123173,
            "transcript": "NM_005631",
            "gDna": "chr7:g.129206473G>A",
            "cDna": "c.1150G>A",
            "protein": "p.D384N",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}